Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with anti viral therapy and vaccine in patients with Hepatitis B chronic infection.
Epistemonikos ID: 4805dd7be970c1e0b0a514514df053b93ec5e8ae
First added on: Mar 23, 2020